相关实验视频

Updated: Jun 5, 2025

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

调节体积调节的离子通道改变了对化疗的敏感性

Lily Elizabeth R Feldman¹, Saswat Mohapatra², Robert T Jones¹

¹Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.

Science advances

|December 13, 2024

概括

敏氨基酶 (NPEPPS) 通过通过体积调节的离子通道 (VRACs) 调节其细胞进口来驱动西斯普拉丁耐药性. 针对NPEPPS可能会改善癌症患者的化疗结果.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
细胞生物学细胞生物学

背景情况:

西斯是许多癌症的基石化疗,但由于耐药性导致的治疗失败显著限制了患者的生存率.
纯甲敏胺酶 (NPEPPS) 已被确定为一个潜在的治疗点,驱动着西斯抗药性.
在NPEPPS中介的西斯普拉丁耐药性背后的精确分子机制仍然不完全理解.

研究的目的:

阐明NPEPPS在各种癌症类型中对西斯普拉丁耐药性的贡献的一般机制.
研究NPEPPS和体积调节的离子通道 (VRACs) 之间的相互作用,以调节西斯的细胞吸收.
为了评估NPEPPS/VRAC基因表达比率作为西斯普拉丁反应的预测生物标志物.

主要方法:

使用癌症模型进行体外和体内实验.
对患者衍生器官的分析.
在多个人类癌症队列中的基因表达分析.
调查NPEPPS和VRACs之间的相互作用.

主要成果:

NPEPPS与VRAC相互作用,以控制西斯的细胞内进口,从而调节细胞对药物的反应.
NPEPPS与VRAC基因表达的比率作为在不同癌症患者群体中西斯普拉丁疗效的预测指标.
这种对青抗性的机制在多种癌症类型中广泛适用.

结论:

NPEPPS和VRAC之间的相互作用是驱动癌症中西斯普拉丁耐药性的关键机制.
针对NPEPPS提供了一个有前途的治疗策略,以克服西斯普拉丁耐药性并改善患者的治疗结果.
NPEPPS/VRAC比率是指导基于的化疗决策的有价值的预测生物标志物.
这些发现还揭示了VRAC调节在正常细胞体积稳态中的作用,其影响超出了癌症治疗范围.

更多相关视频

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Published on: March 16, 2018

相关概念视频

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...

Voltage-gated Ion Channels

Voltage-gated Ion Channels

Voltage-gated ion channels are transmembrane proteins that open and close in response to changes in the membrane potential. They are present on the membranes of all electrically excitable cells such as neurons, heart, and muscle cells.
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several...

Drug Elimination by Renal Route: Tubular Reabsorption

Drug Elimination by Renal Route: Tubular Reabsorption

During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. However, the majority of drugs are either weak acids or weak bases, and their ionization level is dependent on pH. By altering the pH of urine, the...

Drug Elimination by Renal Route: Tubular Secretion

Drug Elimination by Renal Route: Tubular Secretion

Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...